Quality of life among patients after Hodgkin lymphoma treatment: a 3-year prospective study
DOI:
https://doi.org/10.14739/2409-2932.2017.2.103774Keywords:
quality of life, Hodgkin lymphoma, prognosisAbstract
The purpose of the study was to investigate the quality of life among patients after Hodgkin lymphoma treatment to estimate demographic, clinical, psychosocial risk factors of unfavorable prognosis depending on the occurrence of cardiovascular events.
Materials and methods. Population sample was 38 patients after Hodgkin lymphoma treatment. All patients received the interviewer, 35 patients (92.1% of all respondents) answered the questions and were included to the study. Clinical visits have been conducted each month for 3 years after enrollment, during which cardiovascular events have been recorded.
Results: During observation period progression of Hodgkin lymphoma was proved in 8 patients, 3 persons were excluded for poor follow-up. Thirty four cumulative clinical events occurred in 12 patients (50%) within the follow-up, with their distribution being as follows: 2 cardiovascular deaths, 16 cardiac arrhythmias, 6 cardiac ischemic events, 1 stroke, 4 chronic heart failures and 5 hospital admissions for cardiovascular reasons. 3 deaths were not related with cardiovascular pathology or cardiovascular reasons. 3 deaths were not related with cardiovascular pathology.
Patients who had cardiovascular events reported significantly worse physical functioning after anthracyclines with cumulative dose ≥326 mg/m2, after mediastinal radiotherapy. There were significant lower level of vitality in patients with cardiovascular events (p<0.001), in patients with advanced stages and mediastinal radiotherapy. After second-line treatment (MINE) patients had much worse physical functioning (p<0.001) that was associated with quality of life outcomes. There were significant differences in mental health, (р<0.001), role-psychological (р<0.03) scales. The lower level of mental health was associated with disease stages, doses of radiotherapy.
Conclusion: The general health perceptions and vitality levels of Hodgkin lymphoma survivors depends on passed courses of chemotherapy, appearance of cardiovascular events during 3 years.
References
Abrahamsen, A. F., Loge, J. H., Hannisdal, E., Holte, H., & Kvaløy, S. (1998). Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution. Eur. J. Cancer., 34(12), 1865–1870.
(2015). American Cancer Society. What are the Key Statistics about Hodgkin Disease? Retrieved from http://www.cancer.org/cancer/hodgkindisease/detailedguide/hodgkin-disease-key-statistics.
Der-Martirosian, C., Kritz-Silverstein, D., & Barrett-Connor, E. (2010). Five-year stability in associations of health-related quality of life measures in community-dwelling older adults: The Rancho Bernardo Study. Qual Life Res., 19(9), 1333–1341. doi: 10.1007/s11136-010-9700-y.
Favier, O., Heutte, N., Stamatoullas-Bastard, A., Carde, P., Van't Veer, M. B., Aleman, B. M., et al. (2009). Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer., 115(8), 1680–1691. doi: 10.1002/cncr.24178.
Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A(1), et al. (2016). Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N. Engl. J. Med., 374(25), 2419–2429. doi: 10.1056/NEJMoa1510093.
Kiserud, C. E., Loge, J. H., Fosså, A., Holte, H., Cvancarova, M., & Fosså, S. D. (2010). Mortality is persistently increased in Hodgkin's lymphoma survivors. Eur. J. Cancer, 46(9), 1632–1639. doi: 10.1016/j.ejca.2010.02.010.
Norman, G. R., Sloan, J. A., Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation Med. Care., 41(5), 582–592. doi: 10.1097/01.MLR.0000062554.74615.4C
Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., et al. (2015). Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N. Engl. J. Med., 372(17), 1598–1607. doi: 10.1056/NEJMoa1408648.
van Nimwegen, F. A., Schaapveld, M., Janus, C. P., Krol, A. D., Petersen, E. J., Raemaekers, J. M., et al. (2015). Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern. Med., 175(6), 1007–1017. doi: 10.1001/jamainternmed.2015.1180.
Ware, J. E., & Kosinski, Jr., M. (2004) SF-36 Physical and Mental Health Summary Scales: A Manual for Users of Version 1. Lincoln, RI: Quality Metric.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
